AUTHORS
Ravi Kishore Narra, MD.,MS, Krystal Mathew, MD2, Catharine Skoog, PA-C3, Areyl Goff, MSN, NP, RN4, Ravi Shah5, Binod Dhakal, MD, MS6, Sabarinath Venniyil Radhakrishnan, MD7, Carolina D Schinke, MD8, Leo Rasche, PhD9, Aniko Szabo, PhD10, Anita D'Souza Jr, MD11, Meera Mohan, MD, MS12
AFFILIATIONS
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 University of Arkansas Medical Center, Littlerock, United States
9 University of Arkansas Medical Center, Littlerock, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
12 UT MD Anderson Cancer Center, HOUSTON, United States
ABSTRACT
Background: Several lines of evidence suggest multimodality MRD negativity (MRD-), defined as concomitant MRD- in bone marrow (BM), peripheral blood (PB), and novel imaging (NI), is associated with superior outcomes compared with MRD- in a single compartment. There is a lack of robust data on the concordance between these and whether serial PB MRD- predicts BM MRD- in patients treated with IsaR maintenance. Here, we evaluate concordances between BM, NI, and PB MRD and kinetics of PB MRD in the context of a single-center, investigator-initiated, phase II clinical trial investigating the role of IsaR maintenance.
Methods: Elimination of MRD disease after ASCT is a single-center, investigator-initiated, phase II clinical trial investigating the role of IsaR maintenance in patients with persistent BM MRD following ASCT (NCT05690984). Key eligibility criteria include BM MRD+ as measured by ClonoSEQ next-generation sequencing (NGS) following ASCT. The primary endpoint was the proportion of patients achieving BM MRD- at a 10-6 sensitivity, by NGS at the end of 12 cycles of IsaR. All patients had pre-enrolment and end-of-treatment (EOT) NI. PB MRD was measured by MALDI-TOF mass spectrometry using MASS FIX and was considered positive, except when described as monoclonal antibody presence. Serial PB MRD was assessed pre-enrollment, during treatment, and at EOT. Stringent MRD negativity was defined as BM MRD- at 10-6 sensitivity, along with no detectable protein by mass spectrometry, and negative functional imaging.
Results: 30 patients were enrolled, with a median age of 64 years (range 57-68). 43% (n=13) were female, and 17% (n=5) were Black. 21 patients have completed study treatment. 246 multimodality MRD assays were performed in 30 patients at any point. At study enrollment, all patients were BM MRD+ at 10-6, with 70% (n=21) MRD+ at 10-5. NI MRD+ was noted in 17% of patients (n=5) and PB MRD+ in 42% (n=8). During the study, 72 serial PB MRD tests were performed, of which 31% (n=22) were MRD+. 21 patients have completed study treatment, with 11% BM MRD- at 10-6 and 47% BM MRD- at 10-5. NI MRD- was achieved in 71% of patients. Stringent MRD- was attained in 5% (n=1) of patients. PB MRD had 45.3% overall concordance with BM MRD by NGS, with 54.7% of samples discordant. The majority of discordant cases were due to BM MRD+, at 10-6 (Figure 1). Overall concordance rates were higher for BM MRD at 10-5 (64.2%) than at 10-6 (45.3%). PB MRD showed concordance with a combined BM (10-6) and NI MRD of 30.6%, primarily due to failure to detect disease in 71% of patients who were positive by either modality. Serial PB MRD+ was more frequent and of greater magnitude in
patients who were BM MRD+ at 10-5 than at 10-6. Patients who were BM MRD- at 10-6 remained PB MRD- in serial tests preceding.
Conclusion: Serial PB MRD testing may serve as a complementary surveillance tool even in low-disease settings, but it shows modest concordance with BM MRD, particularly at a sensitivity of 10-6.
DISCLOSURES
Ravi Kishore Narra, MD.,MS: AstraZenica - Honoraria; Sanofi - Honoraria; AstraZenica - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)